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Background: Reduced quality of life (QoL) is often the main problem for patients with irritable bowel syndrome
(IBS). This study aimed at finding predictors of reduced physical and mental quality of life (QoL) accessible for
intervention.
Methods: Consecutive patients with IBS (according to the Rome II criteria) visiting a general practitioner were
included in a prospective cohort study and followed up for 6−9 months. At the last visit, information about
sociodemographic characteristics, abdominal complaints, QoL and a range of physical and mental comorbidities
were collected. Physical and mental QoL were measured with the generic QoL instrument Short Form-12 Physical
Component Score (SF-12 PCS) and Short Form-12 Mental Component Score (SF-12 MCS) respectively. The normal
scores are 50. This cross-sectional study used data from the last visit.
Results: Out of 208 patients included in the cohort study, 149 (female/male: 105/44) with a mean age of 52 years
(SD 15.3) were available for the analyses. Physical and mental QoL were reduced, the mean SF-12 PCS and SF-12
MCS scores were 38.4 (SD 11.9) and 45.0 (SD 11.3) respectively. The main independent predictors of low SF-12 PCS
and SF-12 MCS were subjective health complaints and organic diseases, and affective disorders respectively. The
severity of IBS symptoms was of minor clinical importance.
Conclusions: To help patients with IBS and reduced QoL, treatment should focus on QoL and not on relief of IBS
symptoms. The different causes of reduced physical and mental QoL make an individually directed treatment
necessary.
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Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder (FGID). The pooled prevalence
is 11.2 % (95 % CI: 9.8 - 12.8 %) with variations between
countries from 1.1 to 45.0 %. The variation depends in
part on the definition [1, 2]. Although a benign disorder,
the symptoms (abdominal pain, bloating, diarrhoea,
constipation etc.) are bothersome and a burden for the
patients and the society. The disorder is associated* Correspondence: per.farup@ntnu.no
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creativecommons.org/publicdomain/zero/1.0/with decreased QoL as measured with both generic
and disease-specific instruments, a wide range of co-
morbidities, restrictions of social life and high costs of
illness [1, 3–10]. The aetiology and pathogenesis are in
part unknown. No cure exists, and the treatment aims
at teaching patients to cope with the disorder and to
reduce the symptoms with some more or less effective
interventions [11–13].
The prevailing assumption is that the gastrointestinal
symptoms reduce the QoL and bring about the high costs
of illness in patients with IBS. However, a Norwegian
study showed that the comorbidity explained most of the
high costs and could as well explain the reduced QoL [8].
The reduced QoL and the comorbidity are often more
bothersome for patients with IBS than the gastrointestinals article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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generic and disease-specific QoL, but the relative impact
of the IBS severity and the variety of comorbidity on gen-
eric QoL in general, and on physical and mental QoL in
particular, are in large unknown [4, 9, 10, 14–17]. To
find ways to improve the care of patients with IBS, this
study aimed at finding the clinically most important in-
dependent predictors of reduced generic physical and
mental QoL accessible for intervention.
Methods
Study design and participants
Consecutive patients above 17 years of age consulting
26 Norwegian general practitioners (GPs) at nine
health centres during a 10 days’ period in 2001 were
asked about abdominal complaints. Patients with ab-
dominal complaints the last three months, for which
they had consulted or had wanted to consult a GP,
filled in a questionnaire that allowed a diagnosis of IBS
according to the Rome II criteria. To exclude other
diseases, the GPs performed supplementary examina-
tions at their discretion. Patients with IBS were in-
cluded in a six months’ follow-up study. At the end of
the follow-up period, the participants filled in a struc-
tured questionnaire with information about sociode-
mographic characteristics, abdominal complaints, QoL,
and comorbidity. This cross-sectional study used data
from the end of the follow-up period. Design details
are available in previous publications [3, 8, 18–20].
Variables
Four groups of variables were collected: Sociodemographic
characteristics, IBS symptoms, QoL and comorbidity.
Sociodemographic characteristics: Age (years); gender;
daily smoking (yes/no); alcohol use (≤ 2 times per week/> 2
times per week); education (≤ 10 years/> 10 years); and
working status (employed, home worker, disability benefit,
retired, student, not specified).
IBS symptoms: Symptom duration (years); symptom
frequency noted as number of days with symptoms per
week (0, 1−2, 3−4, 4−5, >5; scores 0−4); and symptom
severity (none, mild, moderate, severe; scores 0−3). IBS
symptom intensity score was the product of frequency
and severity (range 0−12).
The health-related quality of life was measured with
Short Form-12 (SF-12). SF-12 contains eight main ele-
ments (general health, physical functioning, bodily pain,
role-physical vitality, social functioning, role-emotional,
and mental health), and summary scores for physical
and mental QoL (SF-12 PCS – physical component
score, and SF-12 MCS – mental component score),
range 0−100. Only the summary scores were used. The
mean summary scores for both SF-12 PCS and SF-12
MCS in the general population are 50 (SD 10) [21].Comorbidity: Number of organic diseases present the
last three months (12 questions about organic diseases,
score 0−12). Subjective Health Complaint inventory
(SHC) measured complaints the last 30 days. The ques-
tionnaire contains 29 questions about common, subject-
ive psychosomatic complaints of which 12 questions
were excluded to avoid duplicate assessment of gastro-
enterological and psychiatric symptoms. The SHC-17
scores subjective somatic complaints (range 0 – 51)
with an adjusted population-based mean score of 6.2
(CI 5.9−6.5). Because SHC-17 uses 17 questions out of
29 questions in the original SHC, the adjusted values
are 17/29 of the SHC-29 scores [22]. Affective disorders
(anxiety and depression) were measured with Hopkins
Symptom Check List-10 (SCL-10; score 1.0 – 4.0).
Values above 1.85 predict affective disorders [23].
Health anxiety was assessed with Whiteley Index (WI)
(score 14−70). The questionnaire has 14 questions related
to fear of disease and perception of body and health;
values > 40 indicate hypochondria [24]. Neuroticism
was assessed with a short form of Eysenck Personality
Questionnaire (EPQ); score 0−10 [25, 26].
Statistics
Depending on the distribution of the data (tested with
the Kolmogorov-Smirnov and Shapiro-Wilk) associa-
tions between QoL and other variables were analysed
with t-test and one-way ANOVA, and correlations with
Pearson and Spearman correlation tests. Missing data
in covariates were handled by multiple imputation. All
variables used in the regression analyses were used in
the imputation model. M = 100 imputed data sets were
created as recommended by van Buuren [27]. The
dependent variables were included as predictors in the
imputation model but were not imputed. The pooled
estimate with CI and p-values were obtained using
Rubin’s rules for multiple imputations. Multiple imput-
ation is a recommended method to include subjects
with partially missing data on covariates in the analyses.
All subjects with complete data on the dependent variable,
and with complete or partially missing data on covariates,
are included in the analysis.
To detect predictors of SF-12 PCS and SF-12 MCS,
the first set of linear regression analyses included all
sociodemographic characteristics, IBS duration and IBS
symptom intensity score and one at the time of each of
the five comorbidities in five consecutive analyses. The
final set of regression analyses performed to detect inde-
pendent predictors of SF-12 PCS and SF-12 MCS in-
cluded all sociodemographic variables, IBS duration, IBS
symptom intensity score, and all the comorbidities that
were significantly associated with SF-12 PCS and SF-12
MCS in the first set of regression analyses. The results
are given as the constants, regression coefficients (B)
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(pc) and p-values. The data were analysed with SPSS
version 20.
Ethics
The study conformed to the principles of the Declaration
of Helsinki and was approved by the Norwegian Regional
Committees for Medical and Health Research Ethics.




830 out of 3369 consecutive patients reported abdominal
complaints the last three months. 278 had IBS according
to the Rome II criteria, of whom 208 were included in
the follow-up study. 149 patients (105 females and 44
men, mean age 52 years) with information about QoL
were available for analyses 6−9 months after inclusion.Fig. 1 Flow chart of the patients in the studyFigure 1 shows a flow chart of the patients with a de-
tailed account for all exclusions, and Table 1 gives the
characteristics of the patients.
QoL
Mean SF-12 PCS and SF-12 MCS were 38.4 (SD 11.9)
and 45.0 (SD 11.3) respectively. SF-12 PCS and SF-12
MCS were negatively associated with IBS symptom in-
tensity score, SHC-17, WI and SCL-10. SF-12 PCS was
also negatively associated with the number of organic
diseases and short education, and SF-12 MCS was
negatively associated with EPQ and smoking. Table 2
gives all associations between the QoL and the patient
characteristics.
Independent predictors of QoL
In the first set of regression analyses, SF-12 PCS was sta-
tistically significantly associated with SHC-17 (pc = -0.470,
p < 0.001), number of organic disease (pc = -0.365, p <
Table 2 Associations between patient characteristics and the physic
Patient characteristics (no of patients) SF-12 PCS
Age (n = 148) r = -0.212
Gender (male/female) 38.9 (12.3)/38.2 (11.8)
Education (< 10 years/10-13 years/> 13 years) 36.8 (11.3)/38.5(12.7)/42.
Daily smoking (yes/no) (n = 138) 38.7 (11.9)/38.6 (12.2)
Alcohol (≤ 2/week/> 2/week) (n = 135) 37.6 (12.2)/41.9 (11.9)
IBS symptom intensity score rho = -0.232
Duration of IBS (n = 133) rho = -0.033
Subjective Health Complaints-17 (n = 148) rho = -0.518
Eysenck Personality Questionnaire (n = 142) rho = -0.024
Whiteley Index (n = 139) rho = -0.395
No. organic diseases rho = -0.407
Hopkins Symptom Check List-10 (n = 141) rho = -0.191
The number of patients available for the analysis is given in brackets (n = x) if less t
SF-12 PCS = Short Form 12 Physical Component Score
SF-12 MCS = Short Form 12 Mental Component Score
The results are given as mean (SD) or correlations with r-value (Pearson) or rho-valu
at-test, “ One-way ANOVA
Table 1 Patient characteristics
Characteristics (no of patients) Results
Female/male 105 (70 %)/44 (30 %)
Age (years) (n = 148) 52.0 (15,3)a
Education (< 10 years/10−13 years/> 13 years) 52 (37 %)/57(41 %)/
31(22 %)
Daily smokers (n = 138) 49 (36 %)
Alcohol use (> 2 times per week) (n = 135) 23 (17 %)
Employment status (n = 140)
Employed 66 (47 %)
Disability benefit 27 (19 %)
Home worker 8 (6 %)
Student 7 (5 %)
Retired 29 (21 %)
Not specified 3 (2 %)
Duration of IBS (Years) (n = 133) 10 (1−55)”
IBS symptom intensity score (score 0−12) 2.0 (0−12)”
Number of organic diseases 2 (0−9)”
Whiteley Index (WI) (n = 139) 25.0 (14.0−60.0)”
Hypochondria (WI > 40) 9 (6 %)
Hopkins Symptom Check List-10 (SCL-10) (n = 141) 1.7 (1.0−3.8)”
Affective disorder (SCL-10 > 1.85) 57 (40 %)
Eysenck Personality Questionnaire (n = 142) 4.0 (0−10.0)”
Subjective Health Complaints-17 (n = 148) 12.0 (0−42)”
SF-12 Physical Component Scale 38.4 (11.9)a
SF-12 Mental Component Scale 45.0 (11.3)a
The number of patients available for the analysis is given in brackets (n = x) if
less than n = 149
Results are given as numbers with percentages, mean with SD (a) or median
with range (”)
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tom intensity score when adjusting for number of organic
diseases and EPQ. SF-12 MCS was statistically signifi-
cantly associated with SCL-10 (pc = -0.656, p < 0.001),
EPQ (pc = -0.567, p < 0.001), WI (pc = -0.441, p < 0.001)
and SHC-17 (pc = -0.182, p = 0.015); and with IBS symp-
tom intensity score except when adjusted for SCL-10. IBS
duration was not statistically significantly associated with
either SF-12 PCS or SF-12 MCS.
The Tables 3 and 4 give the results of the final set of
regression analyses. Independent predictors were socio-
demographic characteristics, IBS duration and IBS
symptom intensity score, and, in addition, the comor-
bidities significantly associated with SF-12 PCS or SF-
12 MCS in the first set of regression analyses. Neither
IBS duration nor IBS symptom intensity score was sta-
tistically significantly associated with QoL. The stron-
gest independent predictors for SF-12 PCS and SF-12
MCS were SHC-17 (pc = -0,304; p < 0.001) and SCL-10
(pc = -0,421; p < 0.001) respectively. The Figs. 2 and 3
show graphic presentations of the most important results.
Discussion
In this study, the comorbidity was the strongest predictor
of reduced general QoL in patients with IBS. Neither IBS
duration nor IBS symptom intensity score was of clinical
significance. These findings have important implications
for the handling of the patients since reduced QoL often is
the main clinical problem.
In this group of patients with IBS recruited in general
practice, both physical and mental QoL were reduced, the
physical component apparently more than the mental one.
Since most studies report reduced QoL in patients withal (SF-12 PCS) and mental (SF-12 MCS) components of QoL
p-value SF-12 MCS p-value
0.010 r = 0.259 0.002
0.736a 47.4 (11.3)/44.0 (11.1) 0.091a
8(11.0) 0.037” 44.5 (10.8)/45.0(11.7)/44.4(10.7) 0.955”
0.976a 42.0 (9.9)/46.4 (11.5) 0.025a
0.119a 45.0 (10.8)/44.2 (12.9) 0.754a
0.004 rho = -0.229 0.005
0.705 r = 0.017 0.844
0.000 rho = -0.283 0.001
0.778 rho = -0.616 < 0.001
< 0.001 rho = -0.441 < 0.001
< 0.001 rho = 0.000 0.995
0.024 rho = -0.695 < 0.001
han n = 149
e (Spearman)
Table 3 Predictors of physical QoL (SF-12 PCS) when adjusting for sociodemographic variables, IBS variables, Subjective Health
Complaints-17, Whiteley Index and number of organic diseases (linear regression analyses with all the reported variables included
in the analysis)
Variable p-value Partial correlation (pc) Regression coefficient B (95 % CI)
Constant 54.25 (47.05; 61.46)
Age (years) 0.050 −0.167 −0.13 (-0.26; -0.00)
Male gender 0.896 −0.011 −0.25 (-3.95; 3.45)
Daily smoking 0.711 −0.032 −0.71 (-4.46; 3.04)
Alcohol more than 2/week 0.306 0.090 2.45 (-2.25; 7.15)
Education (< 10 years/10-13 years/> 10 years) 0.810 0.021 0.31 (-2.25; 2.87)
IBS duration (years) 0.721 0.032 0.02 (-0.09; 0.14)
IBS symptom intensity score 0.434 −0.067 −0.22 (-0.78; 0.34)
Subjective Health Complaints-17 < 0.001 −0.304 −0.49 (-0.74; -0.23)
Whiteley Index 0.090 −0.146 −0.20 (-0.43; 0.03)
Organic disease (number) 0.046 −0.168 −1.07 (-2.12; -0.02)
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recruited in the community will probably have less affec-
tion of QoL, and patients in secondary and tertiary centres
more reduced QoL than in primary care [14]. The reasons
for consultations for IBS vary [28]. In this study, the co-
morbidity and reduced QoL, and not the IBS symptoms,
might have initiated the consultation since the IBS dur-
ation was long (median 10 years) and the IBS symptom
intensity score was low (median score 2). Physical and
mental QoL were normal (approximately 50) if the
characteristics of the patients were normalised (the
constants in the Tables 3 and 4), which indicate that
the most important factors affecting QoL were measured.
The aetiology of reduced generic QoL is complex and
varies between disorders. In one study of patients with
ulcerative colitis and IBS, the most important predic-
tors of reduced QoL were the pain severity and theTable 4 Predictors for SF-12 MCS when adjusting for sociodemogra
Whiteley Index, Hopkins Symptom Check List-10 and Eysenck Person






Alcohol > 2/week .862
Education (<10 years/10-13 years/>10 years) .725
IBS duration (years) .715
IBS symptom intensity score .379
Subjective Health Complaints-17 .448
Whiteley Index .153
Hopkins Symptom Check List-10 < 0.001
Eysenck Personality Questionnaire .050catastrophization respectively [29]. Organic diseases,
unexplained somatic health complaints, affective psy-
chiatric disorders (anxiety and depression), cognitive
dysfunction, major psychiatric disorders (e.g. psychosis)
and social dysfunction all affect QoL. Since IBS has
been associated with most of these complaints and,
therefore, has been classified as a bio-psycho-social dis-
order, reduced QoL is expected.
In this study, the prevalence of comorbidity was high.
The prevalence of subjective health complaints and
affective disorders were twice and nearly four times those
in the general Norwegian population, and 6 % of the pa-
tients had WI scores indicating hypochondria [22, 23]. In
large, the prevalence of comorbidity was in accordance
with previous reports in patients with IBS. However, only
a few studies take into account other organic diseases and
subjective health complaints, and comparative studies withphic variables, IBS variables, Subjective Health Complaints-17,
ality Questionnaire (linear regression analyses with all the reported
Partial correlation (pc) Regression coefficient B (95 % CI)
52.63 (46.81; 58.45)
0.210 0.12 (0.03; 0.21)
0.013 0.23 (-2.73; 3.18)
−0.091 −1.53 (-4.44; 1.37)
−0.015 −0.32 (-3.97; 3.33)
−0.031 −0.36 (-2.38; 1.65)
0.034 0.02 (-0.08; 0.11)
−0.075 −0.20 (-0.64; 0.24)
0.066 0.07 (-0.12; 0.26)
−0.127 −0.15 (-0.37; 0.06)
−0.421 −8.80 (-12.08; -5.53)
−0.174 −0.69 (-1.38; -0.00)
Fig. 2 The associations between physical QoL (SF-12 PCS) and IBS symptom intensity score, number of organic diseases and Subjective Health
Complaints-17 (SHC-17). Presentation of the results from the linear regression analyses
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functions were not studied.
The combination of IBS, a variety of unexplained som-
atic symptoms, organic diseases, psychological affection
and reduced QoL is common. These striking associa-
tions raise the question whether IBS is one distinct dis-
order, several distinct disorders, or only one out of many
symptoms in a generalised systemic disorder. For the
treatment of the patients, these considerations are of
limited interest since no treatment is available for all pa-
tients with IBS. Treatment should focus on the patients’
main symptom(s). In patients in whom reduced overall
QoL is the main symptom, improvement of QoL shouldFig. 3 The associations between mental QoL (SF-12 MCS) and IBS symptom
Symptom Check List-10 (SCL-10). Presentation of the results from the linearbe the primary aim. The treatment of QoL should be
individualised and directed against the cause of reduced
QoL, which varies [14, 16, 29]. To individualise the
treatment, knowledge about the cause of reduced QoL is
mandatory.
This study showed several highly significant associa-
tions between symptoms accessible for intervention and
generic QoL. IBS symptom intensity score, subjective
health complaints, and affective disorders and health
anxiety were associated with reduced physical and men-
tal QoL. In addition, the number of organic diseases was
associated with reduced physical QoL, and neuroticism
with reduced mental QoL. Since the patients presentintensity score, Eysenck Personality Questionnaire (EPQ) and Hopkins
regression analyses
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correlate with QoL, the treatment usually aims at redu-
cing the abdominal symptoms. The wide range of symp-
toms was, however, highly associated with each other
and made analyses of independent predictors necessary.
Analyses of independent predictors including organic
diseases and subjective health complaints have, to our
knowledge, not been performed [4, 16, 29]. In the ana-
lyses of independent predictors of QoL, subjective health
complaints and to a lesser extent organic diseases were
independent predictors of reduced physical QoL, and
affective disorders and neuroticism predicted reduced
mental QoL. It is notable that the cause of reduced
physical and mental QoL differed and that IBS symptom
intensity score did not predict either physical or mental
QoL after adjusting for the comorbidity.
The findings have important clinical implications. The
care of patients with IBS should focus on the main
symptoms. If the main symptom is reduced physical
QoL, the care should focus on relief of subjective health
complaints other than gastrointestinal symptoms (e.g.
muscle-skeletal disorders) and on organic disorders; and
on affective disorders (e.g. anxiety and depression) in pa-
tients with reduced mental QoL [30]. To our knowledge,
the nonsignificant clinical effect of IBS symptoms on
QoL, the inclusion of organic diseases and subjective
health complaints in the evaluations of QoL in patients
with IBS, and the distinction between physical and men-
tal QoL have not previously been reported. An individu-
ally tailored treatment depending on the type and cause
of reduced QoL should be aimed at in patients with IBS
and reduced QoL, and not relief of IBS symptoms.
Strengths and limitations
The inclusion of consecutive patients with abdominal
complaints visiting GPs, the high participation rate
(92 %) and the accordance with other studies indicate a
satisfactory external validity [31]. The follow-up visit was
planned six months after inclusion, but for a minority
the visit took place as late as nine months after inclusion
for practical reasons. In this cross-sectional study, the
patients were asked to report symptoms from the 6−9
months’ study period. Since IBS is an undulating dis-
order, recordings from another period could have
modified the results.
The patients were older than in most other studies.
Age has in most studies a limited effect on QoL in pa-
tients with IBS [30, 32]. In contrast to most other
studies, this study takes into account the somatic co-
morbidity, which is a strength and of importance for
the evaluation of QoL. Patients with somatic comor-
bidity might even have been excluded from other stud-
ies. It is unlikely that the organic disorders caused the
IBS symptoms.The diagnosis of IBS and the measurement of QoL
and the comorbidities were performed with acknowl-
edged instruments validated in Norwegian, and the
range of comorbidities taken into account was high. The
use of a generic QoL questionnaire like SF-12 was
judged as a better overall measure of the patients’ overall
QoL than a disease-specific tool. The impact of IBS
symptom severity is probably higher on the IBS specific
QoL than on the general QoL. A generic QoL instru-
ment was used since the study aimed at finding ways to
improve the patients’ general QoL. Studies and physi-
cians often focus on the disorder and the disease-
specific QoL and forget the patients’ overall complaints.
The use of both a generic and disease-specific QoL
questionnaire would have been preferable. It is likely
that the most important variables influencing QoL were
registered since the physical and mental QoL were nor-
mal (values approximately 50) in patients with low
scores for IBS symptom intensity and no comorbidities,
(i.e. the constants in the multivariable analyses were ap-
proximately 50). In the final dataset used for the multi-
variable analyses, multiple imputations of missing data
were performed. In this study, there were different
predictors of physical and mental QOL, a finding that
deserves attention in clinical practice.
Valid information about current management of the
patients was not available, and ongoing treatment might
have influenced the QoL. The patients were for sure
managed as well as possible according to the GPs’ as-
sessment, and the results give an overall estimate of the
QoL and factors affecting the QoL in patients with IBS
consulting their GP.
The Rome II criteria, and not the new Rome III cri-
teria, were used in the study. A possible misclassification
of the patients due to the use of the Rome II criteria in-
stead of the Rome III criteria was judged as insignificant.
The previously observed poor agreement between the
GPs’ diagnosis of IBS and the Rome criteria reduces the
validity for the use of the results in general practice [19].
The IBS symptom intensity score used in this study is
not a validated tool but has been used in several studies
[1, 3]. It was chosen because it has been used by the
Norwegian Health Authorities in the national health sur-
veys. A validated severity score like “The irritable bowel
severity scoring system” would have been preferable
[33]. The participation rate in the first part of the study
was high, but dropouts and missing data at the final visit
were significant and might have reduced the external
validity. Only 149 out of 278 patients (54 %) with IBS
were available for the analyses. Data “missing not at ran-
dom” (e.g. dropout of patients with low or good QoL)
might have reduced the internal validity [34]. In this study,
most patients had a long duration of IBS. In patients with
new onset of the disease, the results might be different.
Michalsen et al. Health and Quality of Life Outcomes  (2015) 13:113 Page 8 of 9Finally, a cross-sectional study only shows associations
and not causality. Nevertheless, until causality has been
shown in other studies, this information should be used
in the handling of patients with IBS and reduced QoL.
Conclusions
The study indicated that treatment of patients with IBS
and low physical QoL should focus primarily on subjective
health complaints and organic diseases, and in patients
with low mental QoL on affective disorders. The severity
of IBS symptoms was of minor clinical importance for the
physical and mental QoL.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VLM has under supervision, prepared the data for clean file, performed the
statistical analyses, interpreted the results and written the manuscript. POV
has initiated the study together with PGF, collected the data together with
the GPs and in part prepared the data for analyses. PGF is the guarantor,
project leader and main supervisor and has been responsible for the
integrity of the work as a whole from inception to published article. All
authors have read and approved the final manuscript.
Acknowledgements
The authors thank Stian Lydersen, professor in medical statistics at the
Regional Centre for Child and Youth Mental Health and Child Welfare,
Faculty of Medicine, Norwegian University of Science and Technology,
Trondheim for statistical advice, and the participating GPs and their staffs
for their kind collection of data. The study was funded by Department of
Research, Innlandet Hospital Trust, Brumunddal; Faculty of Medicine,
Norwegian University of Science and Technology, Trondheim; and
GlaxoSmithKline, Oslo; Norway.
Author details
1Department of Research, Innlandet Hospital Trust, N-2381 Brumunddal,
Norway. 2Unit for Applied Clinical Research, Department of Cancer Research
and Molecular Medicine, Faculty of Medicine, Norwegian University of
Science and Technology, N-7491 Trondheim, Norway. 3Department of
Medicine, Innlandet Hospital Trust, N-2819 Gjøvik, Norway.
Received: 26 February 2015 Accepted: 21 July 2015
References
1. Vandvik PO, Lydersen S, Farup PG. Prevalence, comorbidity and impact of
irritable bowel syndrome in Norway. Scand J Gastroenterol. 2006;41:650–6.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel
syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–21.
3. Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable
bowel syndrome in general practice: a striking feature with clinical
implications. Aliment Pharmacol Ther. 2004;20:1195–203.
4. Lackner JM, Ma CX, Keefer L, Brenner DM, Gudleski GD, Satchidanand N,
et al. Type, rather than number, of mental and physical comorbidities
increases the severity of symptoms in patients with irritable bowel
syndrome. Clin Gastroenterol Hepatol. 2013;11:1147–57.
5. Amouretti M, Le PC, Gaudin AF, Bommelaer G, Frexinos J, Ruszniewski P,
et al. Impact of irritable bowel syndrome (IBS) on health-related quality of
life (HRQOL). Gastroenterol Clin Biol. 2006;30:241–6.
6. Brun-Strang C, Dapoigny M, Lafuma A, Wainsten JP, Fagnani F. Irritable
bowel syndrome in France: quality of life, medical management, and costs:
the Encoli study. Eur J Gastroenterol Hepatol. 2007;19:1097–103.
7. Canavan C, West J, Card T. Review article: the economic impact of the
irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40:1023–34.
8. Johansson PA, Farup PG, Bracco A, Vandvik PO. How does comorbidity
affect cost of health care in patients with irritable bowel syndrome? A
cohort study in general practice. BMC Gastroenterol. 2010;10:31.9. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of
irritable bowel syndrome in relation to symptoms, health resource
utilization and quality of life. Aliment Pharmacol Ther. 1997;11:553–9.
10. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between
severity of symptoms and quality of life in 858 patients with irritable bowel
syndrome. Gastroenterol Clin Biol. 2004;28:11–5.
11. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and
evidence-based medicine. World J Gastroenterol. 2014;20:6759–73.
12. Hungin AP, Molloy-Bland M, Claes R, Heidelbaugh J, Cayley Jr WE, Muris J,
et al. Systematic review: the perceptions, diagnosis and management of
irritable bowel syndrome in primary care - A Rome Foundation Working
Team Report. Aliment Pharmacol Ther. 2014;40:1133–45.
13. Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid (Online ). 2012;2012.
14. Rey E, Garcia-Alonso MO, Moreno-Ortega M, Alvarez-Sanchez A, Diaz-Rubio
M. Determinants of quality of life in irritable bowel syndrome. J Clin
Gastroenterol. 2008;42:1003–9.
15. Cho HS, Park JM, Lim CH, Cho YK, Lee IS, Kim SW, et al. Anxiety, depression
and quality of life in patients with irritable bowel syndrome. Gut Liver.
2011;5:29–36.
16. Spiegel BM, Gralnek IM, Bolus R, Chang L, Dulai GS, Mayer EA, et al. Clinical
determinants of health-related quality of life in patients with irritable bowel
syndrome. Arch Intern Med. 2004;164:1773–80.
17. Jamali R, Jamali A, Poorrahnama M, Omidi A, Jamali B, Moslemi N, et al.
Evaluation of health related quality of life in irritable bowel syndrome
patients. Health Qual Life Outcomes. 2012;10:12.
18. Vandvik PO, Kristensen P, Aabakken L, Farup PG. Abdominal complaints in
general practice. Diagnoses and characteristics of patients. Scand J Prim
Health Care. 2004;22:157–62.
19. Vandvik PO, Aabakken L, Farup PG. Diagnosing irritable bowel syndrome:
poor agreement between general practitioners and the Rome II criteria.
Scand J Gastroenterol. 2004;39:448–53.
20. Farup PG, Vandvik PO, Aabakken L. How useful are the Rome II criteria for
identification of upper gastrointestinal disorders in general practice? Scand
J Gastroenterol. 2005;40:1284–9.
21. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al.
Cross-validation of item selection and scoring for the SF-12 Health Survey in
nine countries: results from the IQOLA Project. International Quality of Life
Assessment. J Clin Epidemiol. 1998;51:1171–8.
22. Ihlebaek C, Eriksen HR, Ursin H. Prevalence of subjective health complaints
(SHC) in Norway. Scand J Public Health. 2002;30:20–9.
23. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health
status of the Norwegian population: A comparison of the instruments SCL-25,
SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry. 2003;57:113–8.
24. Speckens AE, Spinhoven P, Sloekers PP, Bolk JH, Van Hemert AM. A
validation study of the whitely index, the illness attitude scales, and the
somatosensory amplification scale in general medical and general practice
patients. J Psychosom Res. 1996;40:95–104.
25. Grayson DA. Latent trait analysis of the Eysenck personality questionnaire.
J Psychiatr Res. 1986;20:217–35.
26. Sato T. The Eysenck personality questionnaire brief version: factor structure
and reliability. J Psychol. 2005;139:545–52.
27. van Buuren S. Felxible imputation of missing data. Chapman & Hall /CRC
Press, Taylor & Francis Group, 6000 Broken Sound Parkway NW, Boca Raton,
FL, USA. 2012;49.
28. Hillila MT, Siivola MT, Farkkila MA. Comorbidity and use of health-care
services among irritable bowel syndrome sufferers. Scand J Gastroenterol.
2007;42:799–806.
29. Seres G, Kovacs Z, Kovacs A, Kerekgyarto O, Sardi K, Demeter P, et al.
Different associations of health related quality of life with pain,
psychological distress and coping strategies in patients with irritable bowel
syndrome and inflammatory bowel disorder. J Clin Psychol Med Settings.
2008;15:287–95.
30. Lackner JM, Gudleski GD, Ma CX, Dewanwala A, Naliboff B. Fear of GI
symptoms has an important impact on quality of life in patients with
moderate-to-severe IBS. Am J Gastroenterol. 2014;109:1815–23.
31. Faresjo A, Grodzinsky E, Hallert C, Timpka T. Patients with irritable bowel
syndrome are more burdened by co-morbidity and worry about serious
diseases than healthy controls–eight years follow-up of IBS patients in
primary care. BMC Public Health. 2013;13:832.
32. Minocha A, Johnson WD, Abell TL, Wigington WC. Prevalence,
sociodemography, and quality of life of older versus younger patients
Michalsen et al. Health and Quality of Life Outcomes  (2015) 13:113 Page 9 of 9with irritable bowel syndrome: a population-based study. Dig Dis Sci.
2006;51:446–53.
33. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring
system: a simple method of monitoring irritable bowel syndrome and its
progress. Aliment Pharmacol Ther. 1997;11:395–402.
34. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al.
Multiple imputation for missing data in epidemiological and clinical
research: potential and pitfalls. BMJ. 2009;338:b2393.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
